Enhancing the attractiveness of sarcoma drug development: from rare disease to high-value development platform

Sarcomas are rare and heterogeneous malignancies that account for ∼1% of all cancers and continue to face limited therapeutic innovation relative to other cancers. The combination of rarity, biological diversity, and operational challenges in trial design and patient accrual has historically constrained drug development and contributed to a mismatch between clinical need and industry investment. We present our view that these limitations are largely structural and propose a strategic reframing of selected sarcoma subtypes as high-efficiency settings for precision oncology drug development. Although most sarcomas are genomically complex, specific subsets are characterized by discrete oncogenic dependencies that may enable biomarker-driven approaches with a higher signal-to-noise ratio compared with more heterogeneous malignancies. This positions selected sarcoma contexts as settings for rapid proof-of-mechanism and clinical validation. We outline five key strategies to enhance the attractiveness of sarcoma research to industry stakeholders: (i) development of translational ecosystems integrating patient-derived models, multi-omics and computational tools; (ii) redesign of early-phase clinical trials toward adaptive, biomarker-enriched and signal-seeking platforms; (iii) establishment of academia–industry partnerships and collaborative infrastructures; (iv) improved alignment of regulatory and commercial incentives, including orphan drug pathways and drug repurposing and (v) positioning of sarcomas as high-signal entry points for scalable drug development. However, transferability beyond sarcoma should be considered conditional, being most likely when biological dependencies, biomarkers and pharmacodynamic effects are conserved across tumor types. These approaches support a shift from viewing sarcomas as niche indications to recognizing selected subtypes as strategic platforms capable of de-risking and accelerating broader development programs.